Jazz Pharmaceuticals plc (JAZZ) — Fair Value Analysis
Base-case fair value (P50): $227.30 · Current price: $224.66 · Verdict: Fairly Valued
The Verdict on JAZZ
Based on our proprietary Monte Carlo simulations, JAZZ PHARMACEUTICALS PLC (JAZZ) is currently assessed as Fairly Valued. The analysis indicates a median fair value (P50) of $227.30, which stands very close to its current market price of $224.66. This results in a minimal +1.2% relative to the present valuation, suggesting that the stock price largely reflects the current operational and financial health of the company as projected across thousands of forward scenarios. The Monte Carlo framework accounts for various future uncertainties, positioning JAZZ at a neutral valuation point given its current fundamentals.
How JAZZ stacks up against peers
JAZZ's "average" quality tier indicates that its operational and financial health is generally in line with its sector peers. This average quality profile supports the "Fairly Valued" verdict, as neither exceptional outperformance nor significant underperformance trends are being priced in by the market, according to our simulations. When considering JAZZ's $224.66 against the calculated P50 fair value of $227.30, the narrow +1.2% gap implies that JAZZ’s valuation is consistent with a company exhibiting an average quality tier in its competitive landscape. While specific peer comparisons are dynamic, the qualitative assessment reinforces the market's current appraisal.
What this means for investors
For investors considering JAZZ, the "Fairly Valued" verdict suggests that the immediate upside potential, currently at +1.2% based on the median fair value of $227.30 versus $224.66, is limited. Investors seeking significant short-term gains might find JAZZ less compelling given this tight valuation. However, for those with a long-term perspective and an appreciation for a company with an "average" quality tier, JAZZ may represent a stable holding where value is largely priced in. For a deeper understanding of JAZZ's potential downside scenario (P10) and bull case (P90) distribution, sign up for FairCurve to see the full Monte Carlo simulation range and track JAZZ's fair value as new fundamentals are released.
Frequently Asked Questions
Is JAZZ overvalued or undervalued right now?
Based on our Monte Carlo simulations, JAZZ PHARMACEUTICALS PLC (JAZZ) is currently assessed as Fairly Valued, with a median fair value of $227.30 sitting very close to its current price of $224.66.
What is the bear case and bull case for JAZZ?
The full Monte Carlo distribution, including specific bear-case (P10) and bull-case (P90) price targets, as well as the probability of achieving upside, is available with a free FairCurve account.
How does FairCurve calculate JAZZ's fair value?
FairCurve employs a sophisticated Monte Carlo simulation framework, running thousands of forward-looking financial scenarios to derive a robust fair value distribution for JAZZ PHARMACEUTICALS PLC.
How can I track JAZZ's fair value as it changes?
Add JAZZ to your free FairCurve watchlist to receive daily fair-value updates and instant re-valuation alerts when new earnings reports or other significant fundamental changes occur.